BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21864041)

  • 1. Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
    Grant S
    Leuk Lymphoma; 2011 Sep; 52(9):1623-5. PubMed ID: 21864041
    [No Abstract]   [Full Text] [Related]  

  • 2. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
    Sun JY; Tseng H; Xu L; Hunter Z; Ciccarelli B; Fulciniti M; Zhu B; Maghsoudi K; Yang G; Gong P; Zhou Y; Liu X; Munshi NC; Patterson CJ; Treon SP
    Leuk Lymphoma; 2011 Sep; 52(9):1777-86. PubMed ID: 21657958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation.
    Zhong HM; Ding QH; Chen WP; Luo RB
    Int Immunopharmacol; 2013 Oct; 17(2):329-35. PubMed ID: 23856614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
    Mitsiades N; Mitsiades CS; Richardson PG; McMullan C; Poulaki V; Fanourakis G; Schlossman R; Chauhan D; Munshi NC; Hideshima T; Richon VM; Marks PA; Anderson KC
    Blood; 2003 May; 101(10):4055-62. PubMed ID: 12531799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells.
    Uehara N; Kanematsu S; Miki H; Yoshizawa K; Tsubura A
    Cancer Lett; 2012 Feb; 315(2):112-21. PubMed ID: 22093617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Attkisson E; Dent P; Fisher RI; Friedberg JW; Grant S
    Mol Cancer Ther; 2011 Sep; 10(9):1686-97. PubMed ID: 21750224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine proteases in histone deacetylase inhibitor-induced apoptosis.
    Sonnemann J; Palani CD; Beck LF; Appel B; Beck JF
    Mol Cancer Ther; 2010 Aug; 9(8):2440-1; author reply 2441-2. PubMed ID: 20682651
    [No Abstract]   [Full Text] [Related]  

  • 8. The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.
    Wang D; Zhao M; Chen G; Cheng X; Han X; Lin S; Zhang X; Yu X
    Apoptosis; 2013 Nov; 18(11):1348-1362. PubMed ID: 23708756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of histone deacetylase inhibitors nicotinamide and trichostatin A (TSA) in C17.2 neural stem cells.
    Wang H; Cheng H; Wang K; Wen T
    J Neural Transm (Vienna); 2012 Nov; 119(11):1307-15. PubMed ID: 22407380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
    Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
    J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells.
    Yoshikawa M; Hishikawa K; Idei M; Fujita T
    Eur J Pharmacol; 2010 Sep; 642(1-3):28-36. PubMed ID: 20553909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia.
    Sun JY; Xu L; Tseng H; Ciccarelli B; Fulciniti M; Hunter ZR; Maghsoudi K; Hatjiharissi E; Zhou Y; Yang G; Zhu B; Liu X; Gong P; Ioakimidis L; Sheehy P; Patterson CJ; Munshi NC; O'Connor OA; Treon SP
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):152-6. PubMed ID: 21454220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
    Choi SE; Weerasinghe SV; Pflum MK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6139-42. PubMed ID: 21889343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
    Liu YL; Yang PM; Shun CT; Wu MS; Weng JR; Chen CC
    Autophagy; 2010 Nov; 6(8):1057-65. PubMed ID: 20962572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
    Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.